Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase i and II inhibition Journal Article


Authors: Chaniyara, R.; Tala, S.; Chen, C. W.; Zhang, X.; Kakadiya, R.; Lin, L. F.; Chen, C. H.; Chien, S. I.; Chou, T. C.; Tsai, T. H.; Lee, T. C.; Shah, A.; Su, T. L.
Article Title: Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase i and II inhibition
Abstract: A series of bis(hydroxymethyl)indolizino[6,7-b]indoles and their bis(alkylcarbamates) were synthesized for antitumor studies. These agents were designed as hybrid molecules of β-carboline (topoisomerase inhibition moiety) and bis(hydroxymethyl)pyrrole (DNA cross-linking moiety). The preliminary antitumor studies indicated that these agents exhibited significant cytotoxicity against a variety of human tumor cells in vitro. Treatment of human breast carcinoma MX-1 xenograft-bearing nude mice with compounds 18b and 28c achieved more than 99% tumor remission. We also observed that 18a displayed potent therapeutic efficacy against human lung adenocarcinoma A549 and colon cancer HT-29 xenografts. These results revealed that compound 18a was more potent than irinotecan against HT-29 cells and was as potent as irinotecan against A549 cells in xenograft models. Furthermore, we demonstrated that these derivatives possess multiple modes of action, such as induction of DNA cross-linking, inhibition of topoisomerase I and II, and cell-cycle arrest at the S-phase. © 2013 American Chemical Society.
Journal Title: Journal of Medicinal Chemistry
Volume: 56
Issue: 4
ISSN: 0022-2623
Publisher: American Chemical Society  
Date Published: 2013-02-01
Start Page: 1544
End Page: 1563
Language: English
DOI: 10.1021/jm301788a
PROVIDER: scopus
PUBMED: 23360284
DOI/URL:
Notes: --- - "Export Date: 1 April 2013" - "CODEN: JMCMA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Xiuguo Zhang
    27 Zhang
  2. Ting-Chao Chou
    319 Chou